Latest News

  • 18 Nov 2014

    TapImmune Announces Phase II Clinical Trials Collaboration w...

    Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design SEATTLE, WASHINGTON, November 18, 2014 — TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy...

    more >

  • 22 Oct 2014

    TapImmune Provides Update on PolyStart™ Vaccine Platform A...

    Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox.   SEATTLE, WASHINGTON, October 22, 2014 — TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its...

    more >